Application of radix pseudostellariae cyclic peptide B in antithrombotic drugs

Abstract

The invention discloses an application of radix pseudostellariae cyclic peptide B in antithrombotic drugs, and the radix pseudostellariae cyclic peptide B directly acts on vascular endothelial cells, promotes release of antithrombotic molecules such as nitric oxide and the like, and enhances vasodilatation and antithrombotic ability; the radix pseudostellariae cyclic peptide B can down-regulate expression of thrombus-related genes and reduce generation of thrombus-promoting factors such as inflammatory molecules, and the effects of the radix pseudostellariae cyclic peptide B in the aspects of improving heart functions, promoting angiogenesis and the like indicate that the radix pseudostellariae cyclic peptide B possibly has antithrombotic potential and shows positive effects in improving and preventing thrombus formation and the development process of thrombus. The possibility that the compound is used as a potential antithrombotic drug is strongly indicated, and a new research direction and hope are brought to the field of antithrombotic treatment.

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of Pseudostellariae cyclotide B in antithrombotic drugs. Background Art

[0002] Thrombosis is an important pathological process of many cardiovascular and cerebrovascular diseases. Its mechanism of occurrence is complex, involving platelet aggregation, activation of the coagulation system, changes in blood rheology, and other links. In recent years, with the change of lifestyle and the aggravation of population aging, the incidence of cardiovascular and cerebrovascular diseases has increased significantly, becoming one of the major diseases that seriously threaten human health. Thrombotic diseases include myocardial infarction, cerebral infarction, etc., which seriously threaten human health. Therefore, the exploration and development of effective antithrombotic drugs are of great significance for the prevention and treatment of cardiovascular and cerebrovascular diseases.

[0003] Heterophyllin B (HB) is a natural cyclic peptide compound isolated from Radix Pseudostellariae, which has good biological activity and multiple pharmacological effects. Its pharmacological properties and clinical application potential have gradually attracted attention. Heterophyllin B not only plays an important role in the field of traditional Chinese medicine, but also has made significant progress in the field of medical technology in recent years.

[0004] Existing studies have shown that Pseudostellariae Cyclic Peptide B exhibits significant biological activities in a variety of biological models, including anti-oxidation, anti-inflammatory, anti-tumor, and angiogenesis promotion. In particular, its mechanism of action in promoting angiogenesis may be related to upregulating the expression of vascular endothelial growth factor VEGF165 in vascular endothelial cells, activating the ERK signal transduction pathway downstream of MAPK, and then promoting the proliferation and migration of vascular endothelial cells. This finding suggests that Pseudostellariae Cyclic Peptide B has potential application value in regulating vascular function and improving blood circulation.

[0005] Further studies have also found that Pseudostellariae Cyclic Peptide B also shows significant effects in improving cardiac function. It can inhibit collagen formation in myocardial tissue, maintain mitochondrial homeostasis and mitochondrial autophagy homeostasis in myocardial cells, and inhibit apoptosis in myocardial cells. In addition, Pseudostellariae Cyclic Peptide B can also bind to the mitochondrial antiviral signaling protein MAVS, activate the aggregation and activation of MAVS, induce mitochondrial autophagy signal transduction, thereby mediating the turnover of damaged mitochondria and promoting mitochondrial renewal. These findings provide a new theoretical basis and potential therapeutic targets for the application of Pseudostellariae Cyclic Peptide B in the treatment of cardiovascular diseases.

[0006] With the aging population and the change of lifestyle, thrombotic diseases are frequent. Given the complexity of thrombosis and its close relationship with vascular function and blood circulation, combined with the pharmacological effects of Pseudostellariae Cyclic Peptide B in promoting angiogenesis and improving cardiac function, it can be speculated that Pseudostellariae Cyclic Peptide B may also have potential efficacy in preventing and treating thrombosis. However, the research on Pseudostellariae Cyclic Peptide B in anti-thrombosis is still blank, and further scientific research and clinical verification are urgently needed. Summary of the invention

[0007] Technical issues solved:

[0008] This application aims at the deficiencies in the prior art and solves the technical problems of the current antithrombotic drugs such as large side effects and strong drug resistance. It provides the application of Pseudostellariae Cyclic Peptide B in antithrombotic drugs. Pseudostellariae Cyclic Peptide B can not only effectively prevent the occurrence of thrombosis, but also has a significant alleviating effect on the formed thrombus, especially inflammatory thrombus. It reveals its anti-thrombotic mechanism, optimizes drug preparations and administration methods, develops new anti-thrombotic drugs, improves the treatment effect of thrombotic diseases and promotes the modernization of traditional Chinese medicine.

[0009] Technical solution:

[0010] To achieve the above objectives, this application is implemented through the following technical solutions:

[0011] Application of Pseudostellariae Cyclic Peptide B in antithrombotic drugs.

[0012] Furthermore, the auxiliary materials in the antithrombotic drug include one or more of excipients, diluents, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, and lubricants.

[0013] Furthermore, the antithrombotic drug is in an oral dosage form or a parenteral dosage form.

[0014] Furthermore, the antithrombotic drug is in the form of tablets, capsules, powders, pills, granules, solutions, suspensions, syrups, injections, suppositories, inhalants or sprays.

[0015] Furthermore, the antithrombotic drugs were administered at concentrations of 0, 25, 50, 75, and 100 μM.

[0016] Furthermore, the dosage of the antithrombotic drug was 150 mg / kg in the low concentration group, 300 mg / kg in the medium concentration group, and 600 mg / kg in the high concentration group.

[0017] Furthermore, the frequency of administration of antithrombotic drugs is continuous gavage for 2 weeks, with a frequency of once a day.

[0018] Furthermore, the content of Pseudostellariae Cyclotide B in the anti-thrombotic drug is 99.8%.

[0019] Principle explanation: Pseudostellariae Cyclic Peptide B inhibits the formation of blood clots. On the one hand, it directly acts on vascular endothelial cells, promotes the release of anti-thrombotic molecules such as nitric oxide, and enhances vascular relaxation and anti-thrombotic ability; on the other hand, it can also downregulate the expression of thrombosis-related genes and reduce the production of pro-thrombotic factors such as fibrin. These combined effects together constitute the powerful thrombosis inhibition mechanism of Pseudostellariae Cyclic Peptide B.

[0020] Beneficial effects:

[0021] The present application provides the use of Pseudostellariae Cyclotide B in antithrombotic drugs, which has the following beneficial effects compared with the prior art:

[0022] 1. Develop new antithrombotic drugs. Given the serious side effects and strong drug resistance of current antithrombotic drugs, Pseudostellariae Cyclotide B, as a natural compound, has multiple pharmacological activities and low toxicity, and is expected to become a candidate for new antithrombotic drugs. Through in-depth research on its antithrombotic mechanism, it aims to develop a safe and effective new antithrombotic drug.

[0023] 2. Improve the therapeutic effect of thrombotic diseases. The effects of Pseudostellariae Cyclotide B in improving cardiac function and promoting angiogenesis suggest that it may have anti-thrombotic potential. By applying it to the treatment of thrombotic diseases, it aims to improve the therapeutic effect and reduce the disability and mortality rate of patients;

[0024] 3. Promote the modernization of traditional Chinese medicine. As a traditional Chinese medicine, Pseudostellaria heterophylla has a long history and rich experience in clinical application of traditional Chinese medicine. Studying Pseudostellaria heterophylla cyclopeptide B as an antithrombotic drug will not only help reveal its scientific connotation, but also provide strong support for the modernization of traditional Chinese medicine and promote the international recognition and application of traditional Chinese medicine.

[0025] 4. Pseudostellariae cyclotide B has excellent anti-thrombotic performance. It can protect endothelial cells from oxidative stress and apoptosis. This application reveals the anti-thrombotic mechanism of Pseudostellariae cyclotide B. Through in-depth research on its effects on platelet aggregation, activation of the coagulation system, changes in blood rheology, etc., it aims to reveal its specific anti-thrombotic mechanism and provide a theoretical basis for drug research and development.

[0026] 5. This application optimizes the drug preparation and administration method. In order to improve the anti-thrombotic effect of Pseudostellariae Cyclotide B, it is necessary to optimize its drug preparation and administration method, select a suitable drug carrier, adjust the drug dosage, determine the best administration route, etc., to ensure that the drug is stably released in the body and exerts the best therapeutic effect;

[0027] 6. This application solves the problem of drug side effects and drug resistance. Traditional antithrombotic drugs are often accompanied by certain side effects and drug resistance during use. As a natural compound, Pseudostellariae Cyclotide B has relatively small side effects. Through in-depth research on its safety, effectiveness, possible side effects and drug resistance for long-term use, its safety and reliability in clinical applications can be ensured;

[0028] 7. Enhance the clinical application value of the drug, verify the anti-thrombotic effect of Pseudomonas aeruginosa cyclotide B through clinical trials and practical applications, formulate scientific clinical treatment plans, evaluate the efficacy and safety of the drug, collect feedback from patients, etc., so as to continuously improve and optimize the drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is a diagram of the thrombosis model of mice in which the drug of the present application reduces inflammation;

[0030] Figure 2 The figure shows that the drug of the present application has no toxic effect on endothelial cells; A shows that HUVECs were stimulated with different doses of HB for 6 hours, and the cell viability was analyzed by CCK-8 test; B shows that the cells were pretreated with different concentrations of HB for 12 hours before being exposed to H2O2, and then the cell viability was detected by CCK-8 test;

[0031] Figure 3 For this application, cells were pretreated with HB (25, 50, 100 μM) for 6 h before exposure to H2O2, and then stained with AnnexinV-FITC / PI;

[0032] Figure 4 The drug of this application can reduce endothelial cell apoptosis; A is a graph showing that cells were pretreated with HB (25, 50, 100 μM) for 6 hours before being exposed to H2O2, and the apoptosis rate was detected by flow cytometry after staining with Annexin V-FITC / PI; B is a graph showing that cells were pretreated with HB (25, 50, 100 μM) for 6 hours before being exposed to H2O2, and then the activity of caspase-3 was analyzed, *P<0.05, compared with the control group; #P<0.05, compared with the H2O2 treatment group (n=3);

[0033] Figure 5 In the present application, HUVECs were pretreated with different concentrations of HB and stained with dichlorofluorescein (DCF), and representative micrographs were observed under a fluorescence microscope at a magnification of 200 times;

[0034] Figure 6The figure is a graph showing that the drug of the present application reduces the production of MDA caused by H2O2, wherein A is a graph showing the expression of MDA detected using a malondialdehyde (MDA) kit, B is a graph showing the quantification of DCF fluorescence in a micrograph using ImageProPlus6.0 software, and C is a graph showing the quantification of DCF fluorescence using an enzyme reader; *P<0.05, compared with the control group; #P<0.05, only compared with the hydrogen peroxide group (n=3);

[0035] Figure 7 This is a graph of quantification of DCF fluorescence using flow cytometry in this application;

[0036] Figure 8 The present invention is a graph of thrombosis-related molecules in the in vitro thrombosis model group reduced by the drug of the present invention; wherein A is a graph of the protein expression levels of von Willebrand factor VWF, P-selectin glycoprotein ligand-1 PSGL-1, intercellular adhesion molecule-1 ICAM-1 and vascular cell adhesion molecule-1 VCAM-1 measured by Western blot analysis, after HUVECs were treated with different concentrations (0, 25, 50 and 100 μM) of HB for 6 hours before or without being treated with 200 μM H2O2 for 24 hours, with glyceraldehyde-3-phosphate dehydrogenase (GADPH) as a loading control; B is a graph of the relative expression ratio of VWF and PSGL-1 determined by density analysis; C is a graph of the relative expression ratio of ICAM-1 and VCAM-1 determined by density analysis Expression ratio diagram; D is the mRNA expression diagram of VWF and PSGL-1 in different groups studied by reverse transcription polymerase chain reaction (RT-PCR); E is the mRNA expression diagram of ICAM-1 and VCAM-1 in different groups studied by reverse transcription polymerase chain reaction (RT-PCR); F is the expression diagram of NO detected by NO kit after cells were treated with 0 or 100 μM HB for 6 hours, and then treated with or without H2O2 for 24 hours, *P<0.05, compared with the control group; #P<0.05, only compared with the hydrogen peroxide group (n=3);

[0037] Fig. 9It is a graph showing that the drug of the present application reduces the expression of inflammatory molecules in an in vitro thrombosis model group; wherein A is a graph measured by Western blot analysis, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control, B is a graph showing the protein expression levels of TNF-α, IL-1β and IL-6 in HUVECs after being treated with 0, 25, 50 and 100 μM HB for 6 hours before or without being treated with 200 μM H2O2 for 24 hours; C is a graph showing the mRNA expression of TNF-α, IL-1β and IL-6 in different groups detected by reverse transcription polymerase chain reaction (RT-PCR); D is a graph showing the content of TNF-α, IL-1β and IL-6 in the culture supernatant detected by enzyme-linked immunosorbent assay (ELISA), *P<0.05, compared with the control group; #P<0.05, compared with the H2O2 treatment group (n=3);

[0038] Fig.10 It is a model diagram of the drug of the present application reducing the tail blood flow of inflammatory mouse thrombosis; wherein A is a diagram of thrombus length, B is a diagram of carrageenan-induced mouse tail thrombosis rate; C is a blood flow diagram, and D is a quantitative diagram of the tail blood flow of HB reducing thrombosis in carrageenan-induced mouse thrombosis, ##p<0.01 compared with the untreated group, **p<0.01 compared with the model group (n=8);

[0039] Fig.11 This is a hematoxylin-eosin (H&E) staining diagram of the drug of the present application reducing the liver, lung and tail tissues of mice at 2, 4 and 6 cm away from the tail tip, and blood vessels and thrombi are represented by blue and red dotted lines, respectively;

[0040] Fig.12 The figures are images showing that the drug of the present application reduces thrombosis in the liver, lung and tail of mice, wherein A is an H&E staining image of lung tissue, in which venous thrombosis is indicated by a black arrow; B is an H&E staining image of liver tissue, in which hepatic vein thrombosis is indicated by a blue arrow (n=8). DETAILED DESCRIPTION

[0041] In this section, the specific embodiments of this patent application will be described in detail in conjunction with the accompanying drawings, aiming to provide a clear and comprehensive description of the technical solution. It should be clear that the embodiment described here only represents one of the possible applications of this patent and does not represent all possible implementation methods. Based on the content of this document, a person of ordinary skill in the art can derive all other potential embodiments covered by this application without performing any creative work. Therefore, these embodiments should all be deemed to be within the scope of protection of this patent.

[0042] Example 1

[0043] Establishing an in vitro inflammatory thrombotic model in endothelial cells and verifying drug effects:

[0044] In order to simulate the complex process of thrombosis in vivo, an in vitro inflammatory thrombosis model based on endothelial cells was constructed. 200 μM H2O2 was added to each well to stimulate endothelial cells and incubated for 24 hours to induce an inflammatory response, accompanied by enhanced oxidative stress and upregulated expression of thrombosis-related molecules.

[0045] Drug intervention and effect verification: Pseudo-P ...

[0046] As expected, HB did not cause damage to HUVECs. On the contrary, it significantly inhibited the expression of inflammatory factors IL-1β, IL-6, TNF-α, and the expression of thrombosis-related molecules PSGL-1, VWF, VCAM-1, and ICAM-1, while promoting the expression of vasodilator factor NO. In addition, HB effectively inhibited the production of ROS in HUVECs stimulated by H2O2 by activating the NRF2 / HO-1 pathway, while inhibiting the apoptosis of these cells under H2O2 stimulation. Notably, the inhibition of the NRF2 / HO-1 pathway partially reversed the beneficial effects of HB on HUVECs. Oral administration of HB at doses of 150 mg / kg, 300 mg / kg, and 600 mg / kg significantly reduced carrageenan-induced thrombosis in the lungs, liver, and tail of mice, while increasing tail blood flow.

[0047] The comprehensive verification of anti-thrombotic activity used a variety of high-precision biotechnology methods, which not only deeply analyzed the anti-inflammatory and antioxidant mechanisms of Pseudo-P ...

[0048] A comprehensive safety and toxicity assessment was conducted on Pseudostellariae Cyclic Peptide B. The results showed that the compound has good safety within the prescribed dosage range and has no obvious toxic side effects, providing a reliable safety guarantee for the clinical application of Pseudostellariae Cyclic Peptide B.

[0049] Compared with traditional antithrombotic drugs, Pseudomonas aeruginosa Cyclic Peptide B has unique advantages in many aspects. First, it has stronger anticoagulant and thrombosis inhibition capabilities; second, it has higher safety and fewer toxic side effects. These advantages make Pseudomonas aeruginosa Cyclic Peptide B more competitive in the antithrombotic drug market.

[0050] The multi-target therapeutic mechanism of Pseudostellariae Cyclic Peptide B in treating thrombosis is different from traditional drugs that inhibit thrombosis through a single pathway. Pseudostellariae Cyclic Peptide B can simultaneously act on multiple physiological and pathological processes related to thrombosis, including protecting vascular endothelial cells and reducing inflammatory responses. This multi-target mode of action enables Pseudostellariae Cyclic Peptide B to produce a more comprehensive and lasting therapeutic effect in treating thrombosis, effectively reducing the recurrence rate of thrombosis.

[0051] Example 2

[0052] Precise optimization of drug delivery regimen:

[0053] Based on the pharmacokinetic properties of the drug, through repeated experiments and data analysis, in the in vitro experimental stage, this application uses a variety of technical means to conduct a detailed analysis of the survival status of cells at different drug concentrations. Specifically, through direct observation under a microscope, this application can intuitively evaluate the morphology and vitality of cells; at the same time, with the help of advanced cell proliferation detection methods such as CCK-8 and MTT, this application quantifies the specific effects of drug treatment on cell survival rate. After rigorous data collection and two-way comparative analysis, this application finally determined 100μM as the optimal experimental concentration of the drug. This concentration not only ensures the experimental effect, but also ensures the reliability and accuracy of the results. In the in vivo experiment, this application carefully designed a variety of grouping and dosing schemes, and comprehensively explored the therapeutic effects of drugs under different conditions by adjusting the method and frequency of administration. Specifically, by carefully observing the blood flow conditions of the mouse tail, combined with an in-depth analysis of the thrombosis of the liver, lungs and tail, this application finally determined a dose of 300kg / mg and the optimal feeding method. This program not only effectively reduced thrombosis in mice, but also demonstrated stable and lasting therapeutic effects, providing a solid experimental basis for subsequent drug development and application.

[0054] Although traditional antithrombotic drugs such as anticoagulants and antiplatelet drugs have certain therapeutic effects, they also have some shortcomings, such as easy bleeding and large side effects. In order to further explore the potential of Pseudostellariae Cyclic Peptide B, this application directly uses mice as an experimental model and carefully designs a comparative study with aspirin as a positive control. The experimental results show that compared with the classic drug aspirin, Pseudostellariae Cyclic Peptide B not only shows a stronger effect in anti-thrombotic effect, but also does not show an increasing trend in the key safety indicator-bleeding risk. This finding is particularly striking.

[0055] Example 3

[0056] Verify the harmlessness and protective effect of drugs on endothelial cells:

[0057] Endothelial cells are the first barrier of the vascular lining, and their healthy state is crucial to maintaining blood circulation and preventing thrombosis. In order to comprehensively evaluate the safety and protective potential of Pseudomonas aeruginosa cyclotide B, this application designed a series of in vitro experiments to carefully examine its effects on endothelial cells.

[0058] Cell viability and morphology assessment:

[0059] First, this application constructed an endothelial cell culture system and introduced different concentrations (0, 25, 50, 75, 100 μM) of Pseudostellariae Cyclic Peptide B for exposure treatment. Subsequently, the cell viability was evaluated using a highly sensitive CCK-8 kit. The results showed that within the above concentration range, Pseudostellariae Cyclic Peptide B effectively antagonized the harmful effects of H2O2 on cell viability in a dose-dependent manner, demonstrating its powerful cell protective effect. In order to further verify this finding, this application used a microscope to carefully observe the morphological changes of cells under treatment at each concentration. The observation results further confirmed that within the expected therapeutic concentration range, Pseudostellariae Cyclic Peptide B did not cause significant toxic effects on cells, ensuring its safety and feasibility in clinical applications.

[0060] Cell function assay:

[0061] The apoptosis rate was detected by flow cytometry. After treatment under specific conditions, the cells were treated with trypsin and harvested. The cells were then resuspended in 195 μL of binding buffer. Subsequently, 5 μL of Annexin V-FITC and 10 μL of Annexin V binding buffer were added, and the cells were incubated in the dark for 20 minutes. Finally, all specimens were analyzed by flow cytometry. The test results showed that the drug could reduce endothelial cell apoptosis.

[0062] An animal model related to inflammatory thrombotic diseases was constructed, and the experimental results showed that after treatment with Pseudostellariae Cyclic Peptide B, the thrombosis in the animal model was significantly reduced. These results fully demonstrated the effectiveness of Pseudostellariae Cyclic Peptide B in the prevention and treatment of thrombotic diseases.

[0063] In vivo experiments constructed a mouse inflammatory thrombosis model, and induced an inflammatory response in mice by injecting carrageenan, as follows: BALB / c mice (male / female, 18-22g) were selected, and 12 days after the start of the administration period, all groups except the control group were intraperitoneally injected with 10μl / g carrageenan solution, with a dose of 100mg / kg body weight.

[0064] Drug intervention and observation: Mouse inflammatory thrombosis model, inflammatory response was induced in mice by injection of carrageenan, as follows: 48 mice were randomly divided into 6 groups, 8 mice in each group: untreated group, model group, HB prevention low dose group (150 mg / kg), HB prevention medium dose group (300 mg / kg), HB prevention high dose group (600 mg / kg) and aspirin (20 mg / kg) group. The initial group and model group were gavaged with normal saline (PBS) for 2 weeks, the prevention group was gavaged with HB suspension, and the aspirin group was gavaged with aspirin (20 mg / kg), with the same frequency, and continued for 4 weeks. 12 days after the start of the administration period, all groups except the control group were intraperitoneally injected with 10 μl / g carrageenan solution at a dose of 100 mg / kg body weight. Two days later, all mice were anesthetized with 1% sodium pentobarbital. The researchers took pictures of the mice's tails and immediately assessed their blood flow. Subsequently, blood, tail tissue, liver and lung samples were collected.

[0065] Efficacy evaluation: The thrombosis rate, thrombus size, and vascular patency of each group of mice were compared. After the experiment, a laser blood flow meter was used to detect blood flow abundance and observe color changes. Low perfusion was displayed as dark blue and high perfusion was displayed as bright red. The mice were then killed by dislocating the neck. The tail tissue of the mice was taken. Tissues at 2, 4, and 6 cm from the tip of the tail and liver and lung tissues were taken. HE staining was performed to observe vascular embolism. The tail tissue of the mice was taken and ground to obtain protein and RNA. WB and PCR tests were performed on thrombosis-related molecules. During the analysis of the laser blood flow meter, color changes were observed. Low perfusion was displayed as dark blue and high perfusion was displayed as bright red. After HE staining, the vascular blockage of the tissue was observed under a microscope. The result was that in different groups, the thrombosis of mice at a drug concentration of 300 mg / kg was better than that of traditional drugs in preventing thrombosis. The safety and effectiveness of the drug were comprehensively judged, and the degree of thrombosis and the number of mouse deaths at the corresponding concentration were determined. The expected results show that Pseudostellariae Cyclic Peptide B exhibits excellent effects in preventing thrombosis, and has higher efficacy and lower adverse reaction rate than traditional drugs.

[0066] Conclusion and Outlook

[0067] Through the above research, this application successfully verified the multiple effects of Pseudomonas aeruginosa cyclotide B in protecting endothelial cells, inhibiting inflammatory response and oxidative stress, and preventing thrombosis, laying a solid foundation for the widespread application of this drug.

[0068] By simulating the thrombosis process in the human body and taking into account the important role of inflammatory factors in thrombosis, Pseudostellariae Cyclic Peptide B showed remarkable preventive and therapeutic effects in this model, not only significantly reducing the number and volume of thrombi, but also effectively protecting the integrity of vascular endothelial cells and avoiding further damage. This discovery not only provides strong evidence support for the potential clinical application of Pseudostellariae Cyclic Peptide B, but also opens up a new research direction for the development of new, highly effective and low-toxic antithrombotic drugs.

[0069] In summary, this application has fully revealed the unique advantages and important role of Pseudostellariae Cyclic Peptide B in the prevention and treatment of thrombotic diseases through a series of in-depth and systematic experimental studies. This research result not only provides valuable scientific basis and technical support for drug development in related fields, but also brings new hope and good news for the treatment of patients with thrombotic diseases. Pseudostellariae Cyclic Peptide B will play a more important role in the future medical field and contribute more to the health of mankind.

[0070] The above description has fully disclosed the specific embodiments of the present invention. It should be pointed out that any changes made by those skilled in the art to the specific embodiments of the present invention do not deviate from the scope of the claims of the present invention. Accordingly, the scope of the claims of the present invention is not limited to the above specific embodiments.

Claims

1. Application of Pseudostellariae Cyclic Peptide B in antithrombotic drugs.

2. The use according to claim 1, characterized in that: The excipients in antithrombotic drugs include one or more of excipients, diluents, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, and lubricants.

3. The use according to claim 1, characterized in that: Antithrombotic drugs are available in oral or parenteral formulations.

4. The use according to claim 1, characterized in that: Antithrombotic drugs are in the form of tablets, capsules, powders, pills, granules, solutions, suspensions, syrups, injections, suppositories, inhalants or sprays.

5. The use according to claim 1, characterized in that: The antithrombotic drugs were administered at concentrations of 0, 25, 50, 75, and 100 μM.

6. The use according to claim 1, characterized in that: The dosage of antithrombotic drugs was 150 mg / kg in the low concentration group, 300 mg / kg in the medium concentration group, and 600 mg / kg in the high concentration group.

7. The use according to claim 1, characterized in that: The frequency of administration of antithrombotic drugs is continuous gavage once a day for 2 weeks.

8. The use according to claim 1, characterized in that: The content of Pseudostellariae Cyclotide B in antithrombotic drugs is 99.8%.

Images